	US 11,986,495 B2
	Method of treatment
Mariapia A. Degli-Esposti, Nedlands (AU); Geoffrey R. Hill, Hawthorne (AU); Christopher E. Andoniou, Woodbridge (AU); and Peter Fleming, Samson (AU)
Assigned to Lions Eye Institute Limited, Nedlands (AU); and QIMR Berghofer Medical Research Institute, Herston (AU)
Appl. No. 16/767,060
Filed by Lions Eye Institute Limited, Nedlands (AU); and QIMR Berghofer Medical Research Institute, Herston (AU)
PCT Filed Nov. 28, 2018, PCT No. PCT/AU2018/051271 § 371(c)(1), (2) Date May 26, 2020, PCT Pub. No. WO2019/104384, PCT Pub. Date Jun. 6, 2019.
Claims priority of application No. 2017904807 (AU), filed on Nov. 28, 2017.
Prior Publication US 2020/0289559 A1, Sep. 17, 2020
Int. Cl. A61K 35/16 (2015.01); A61P 31/20 (2006.01); C07K 16/42 (2006.01)

CPC A61K 35/16 (2013.01) [A61P 31/20 (2018.01); C07K 16/4283 (2013.01)]

13 Claims

1. A method for inhibiting cytomegalovirus (CMV) reactivation in a transplant recipient with a CMV-seropositive serological status, the method comprising obtaining serum and/or plasma from the transplant recipient prior to transplantation and administering an effective amount of the serum and/or plasma, or a component thereof, to the transplant recipient before, concomitant with or after transplantation, wherein the serum or plasma or component thereof comprises one or more anti-CMV antibodies.